拜玛林制药(BMRN)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BMRN 拜玛林制药

已收盘 07-08 16:00:00 EDT

59.75

-0.60

-0.99%

盘后59.64

-0.11-0.18%

19:59 EDT

最高60.67	最低59.63	成交量154.56万
今开59.88	昨收60.35	日振幅1.72%
总市值115.48亿	流通市值114.79亿	总股本1.93亿
成交额9,256万	换手率0.80%	流通股本1.92亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"BMRN","market":"US","secType":"STK","nameCN":"拜玛林制药","latestPrice":59.75,"timestamp":1783540800000,"preClose":60.35,"halted":0,"volume":1545555,"hourTrading":{"tag":"盘后","latestPrice":59.64,"preClose":59.75,"latestTime":"19:59 EDT","volume":63690,"amount":3806544.1572,"timestamp":1783555196108,"change":-0.11,"changeRate":-0.001841,"amplitude":0.006862},"delay":0,"changeRate":-0.009942004971002508,"floatShares":192116189,"shares":193270028,"eps":1.39,"marketStatus":"已收盘","change":-0.6,"latestTime":"07-08 16:00:00 EDT","open":59.88,"high":60.67,"low":59.63,"amount":92556295.313625,"amplitude":0.017233,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":1.39,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1783584000000},"marketStatusCode":5,"adr":0,"adrRate":0,"listingDate":932702400000,"exchange":"NASDAQ","adjPreClose":60.35,"preHourTrading":{"tag":"盘前","latestPrice":59.84,"preClose":60.35,"latestTime":"09:29 EDT","volume":1520,"amount":91466.32376,"timestamp":1783517399999,"change":-0.51,"changeRate":-0.008451,"amplitude":0.024262},"postHourTrading":{"tag":"盘后","latestPrice":59.64,"preClose":59.75,"latestTime":"19:59 EDT","volume":63690,"amount":3806544.1572,"timestamp":1783555196108,"change":-0.11,"changeRate":-0.001841,"amplitude":0.006862},"volumeRatio":0.957668,"impliedVol":0.4237,"impliedVolPercentile":0.6494},"requestUrl":"/m/hq/s/BMRN","defaultTab":"news","newsList":[{"id":"1127221100","title":"拜玛林制药III期研究显示第52周时年化生长速度增加2.33厘米/年","url":"https://stock-news.laohu8.com/highlight/detail?id=1127221100","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1127221100?lang=zh_cn&edition=full","pubTime":"2026-05-21 04:21","pubTimestamp":1779308506,"startTime":"0","endTime":"0","summary":"拜玛林制药公司公布的一项III期临床试验数据显示，在治疗第52周时，患者的年化生长速度实现了显著提升，增幅达到2.33厘米/年。这一积极结果凸显了其在研疗法在促进生长方面的潜力，为后续的研发与审批进程提供了关键支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4566","BMRN","IE00B7SZLL34.SGD","IE0002270589.USD","IE00B19Z3B42.SGD","BK4139","IE00B19Z3581.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151320774","title":"拜玛林制药宣布Voxzogo® (Vosoritide) 在软骨发育不全儿童中取得积极三期关键研究结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1151320774","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1151320774?lang=zh_cn&edition=full","pubTime":"2026-05-21 04:21","pubTimestamp":1779308486,"startTime":"0","endTime":"0","summary":"拜玛林制药公布了其药物Voxzogo® (Vosoritide) 针对软骨发育不全儿童患者的三期关键性研究的积极成果。该研究达到了主要终点，显示治疗取得了显著效果。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z3581.USD","IE00B19Z3B42.SGD","BMRN","IE0002270589.USD","IE00B7SZLL34.SGD","BK4139","BK4566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101027296","title":"基因疗法后期试验结果喜忧参半，拜玛林制药股价应声下跌1%","url":"https://stock-news.laohu8.com/highlight/detail?id=1101027296","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1101027296?lang=zh_cn&edition=full","pubTime":"2026-05-18 21:47","pubTimestamp":1779112039,"startTime":"0","endTime":"0","summary":"拜玛林制药（Biomarin Pharmaceutical）一项针对遗传性疾病的疗法在后期研究中呈现出复杂的数据结果，市场对此反应审慎，公司股价应声下跌约1%。\n这项关键临床试验的结果未能提供明确一致的成功信号，导致投资者信心受挫。尽管疗法在某些评估指标上显示出积极潜力，但整体数据的混合性引发了对其最终疗效与商业化前景的重新评估。\n股价的即时波动反映了市场对生物科技公司研发管线不确定性的典型定价行为。在高度依赖单一或少数重磅产品驱动的行业里，临床数据的任何模糊性都可能迅速转化为资本市场的压力。此次下跌凸显了在创新疗法开发过程中，从科学验证到市场接纳所面临的严峻挑战。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BMRN","BK4139","IE00B19Z3581.USD","IE0002270589.USD","IE00B19Z3B42.SGD","IE00B7SZLL34.SGD","BK4566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184770893","title":"拜玛林制药ENERGY 3研究：放射学整体印象变化评分未现改善","url":"https://stock-news.laohu8.com/highlight/detail?id=1184770893","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1184770893?lang=zh_cn&edition=full","pubTime":"2026-05-18 21:11","pubTimestamp":1779109895,"startTime":"0","endTime":"0","summary":"拜玛林制药公司近日公布的ENERGY 3研究结果显示，其评估指标——放射学整体印象变化评分——并未出现具有统计学意义的改善。这一核心数据未能达到研究预设的终点，引发了市场对该疗法潜在疗效的进一步审视。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0002270589.USD","IE00B19Z3B42.SGD","IE00B19Z3581.USD","BMRN","BK4566","BK4139","IE00B7SZLL34.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198173165","title":"拜玛林制药：佝偻病严重程度评分与生长Z评分等次要终点未见积极趋势","url":"https://stock-news.laohu8.com/highlight/detail?id=1198173165","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1198173165?lang=zh_cn&edition=full","pubTime":"2026-05-18 21:07","pubTimestamp":1779109622,"startTime":"0","endTime":"0","summary":"拜玛林制药公司近日公布的数据显示，其研究中的关键次要终点，包括佝偻病严重程度评分与生长Z评分，均未观察到积极的改善趋势。\n这一结果引发了市场对其相关疗法前景的进一步审视。分析人士指出，次要终点的表现对于全面评估治疗效果至关重要，当前数据的缺乏亮点可能意味着需要更深入的分析或更长的观察周期。\n公司方面尚未就这些具体数据发表进一步评论。投资者正密切关注后续可能披露的更多细节，以评估其对整体研发管线价值的影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0002270589.USD","BK4139","BMRN","BK4566","IE00B7SZLL34.SGD","IE00B19Z3B42.SGD","IE00B19Z3581.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186367310","title":"拜玛林制药Bmn 401在ENERGY 3研究中显示血浆无机焦磷酸盐显著增加","url":"https://stock-news.laohu8.com/highlight/detail?id=1186367310","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1186367310?lang=zh_cn&edition=full","pubTime":"2026-05-18 21:06","pubTimestamp":1779109609,"startTime":"0","endTime":"0","summary":"拜玛林制药公司宣布，其候选药物Bmn 401在ENERGY 3研究中的数据显示，能够显著提升患者血浆中的无机焦磷酸盐水平。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IE00B19Z3581.USD","IE00B19Z3B42.SGD","IE00B7SZLL34.SGD","BMRN","BK4566","IE0002270589.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192554879","title":"拜玛林制药在儿科内分泌学会2026年会公布Voxzogo长期治疗对软骨发育不全患儿臂展、骨骼健康及生长影响的新数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1192554879","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1192554879?lang=zh_cn&edition=full","pubTime":"2026-05-03 03:30","pubTimestamp":1777750216,"startTime":"0","endTime":"0","summary":"拜玛林制药于儿科内分泌学会2026年度会议上，公布了关于Voxzogo长期治疗对软骨发育不全患儿臂展、骨骼健康及生长影响的最新研究数据。该研究深入探讨了Vosoritide持续用药对患儿多项生理指标产生的积极效果。\n最新分析结果显示，长期接受Voxzogo治疗的患儿在臂展发育、骨骼健康指标及整体生长参数方面均表现出显著改善。这些发现为Vosoritide在改善软骨发育不全患儿生活质量方面的长期疗效提供了重要临床证据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BMRN","IE00B7SZLL34.SGD","IE00B19Z3B42.SGD","IE0002270589.USD","BK4566","IE00B19Z3581.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157902853","title":"拜玛林制药：因两项研究者发起试验中发生多起股骨头骨骺滑脱事件而决定终止研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1157902853","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1157902853?lang=zh_cn&edition=full","pubTime":"2026-03-16 20:35","pubTimestamp":1773664512,"startTime":"0","endTime":"0","summary":"拜玛林制药宣布，由于两项正在进行的研究者发起试验中出现了数例股骨头骨骺滑脱事件，公司已决定终止这些研究项目。该决定基于对患者安全的审慎评估，旨在优先保障临床试验参与者的福祉。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IE00B19Z3581.USD","IE00B19Z3B42.SGD","IE00B7SZLL34.SGD","BMRN","BK4566","IE0002270589.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158176505","title":"拜玛林制药Voxzogo®获加拿大卫生部附条件批准 用于软骨发育不全症治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1158176505","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1158176505?lang=zh_cn&edition=full","pubTime":"2026-02-11 20:10","pubTimestamp":1770811832,"startTime":"0","endTime":"0","summary":"拜玛林制药（Biomarin Pharmaceutical）近日宣布，其治疗软骨发育不全症的药物Voxzogo®已获得加拿大卫生部颁发的附条件合规通知。这一批准标志着该药物在加拿大市场迈出重要一步，为当地患者提供了新的治疗选择。\n软骨发育不全症是一种罕见的遗传性疾病，主要特征为骨骼发育异常。Voxzogo®作为一种创新疗法，其获批将为符合特定条件的患者群体带来希望。加拿大卫生部的附条件批准通常基于药物显示的潜在临床效益，同时要求制药公司继续开展相关研究以进一步验证疗效与安全性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0002270589.USD","BK4139","BMRN","IE00B19Z3581.USD","IE00B19Z3B42.SGD","IE00B7SZLL34.SGD","BK4566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103610111","title":"拜玛林制药敲定高级票据私募发行价格，并完成新高级担保定期贷款银团组建","url":"https://stock-news.laohu8.com/highlight/detail?id=1103610111","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1103610111?lang=zh_cn&edition=full","pubTime":"2026-01-30 05:06","pubTimestamp":1769720774,"startTime":"0","endTime":"0","summary":"拜玛林制药已确定其高级票据的私募发行价格，同时宣布成功组建新的高级担保定期贷款银团。这两项融资举措的完成，标志着公司在优化资本结构方面取得了重要进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z3581.USD","BK4139","IE00B7SZLL34.SGD","IE00B19Z3B42.SGD","IE0002270589.USD","BMRN","BK4566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199936217","title":"拜玛林制药宣布拟进行优先票据私募发行并启动新优先担保定期贷款银团融资","url":"https://stock-news.laohu8.com/highlight/detail?id=1199936217","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1199936217?lang=zh_cn&edition=full","pubTime":"2026-01-26 20:47","pubTimestamp":1769431635,"startTime":"0","endTime":"0","summary":"拜玛林制药(BMRN)最新披露，公司将启动两项重要融资安排：一方面计划以非公开方式发行优先票据，另一方面正牵头组织新的优先担保定期贷款银团融资项目。\n该生物制药巨头通过双重融资策略优化资本结构，优先票据私募发行将面向合格机构投资者，而银团贷款方案则通过联合多家金融机构共同提供资金支持。这两项融资举措将为企业研发管线推进和全球业务扩张提供战略性资金保障。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BMRN","BK4139","IE0002270589.USD","IE00B19Z3B42.SGD","IE00B7SZLL34.SGD","BK4566","IE00B19Z3581.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102753463","title":"Canaccord Genuity上调拜玛林制药评级至买入 目标价大幅提升至98美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1102753463","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1102753463?lang=zh_cn&edition=full","pubTime":"2026-01-20 13:27","pubTimestamp":1768886841,"startTime":"0","endTime":"0","summary":"投资机构Canaccord Genuity近日发布最新研报，将拜玛林制药（Biomarin Pharmaceutical）的投资评级从\"持有\"显著上调至\"买入\"级别。与此同时，该机构将其目标股价从原先的84美元大幅调升至98美元，显示出对该公司未来发展的强烈信心。\n此次评级调整反映了分析师对拜玛林制药核心业务增长前景的乐观预期。目标价的大幅提升也预示着该机构认为公司股价具备可观的上涨空间。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IE00B19Z3581.USD","IE0002270589.USD","BK4566","IE00B19Z3B42.SGD","IE00B7SZLL34.SGD","BMRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513372995","title":"奥本海默：上调Biomarin Pharmaceutical(BMRN.US)评级，由Perform调整至优于大市评级, 目标价98.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2513372995","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513372995?lang=zh_cn&edition=full","pubTime":"2025-02-24 21:17","pubTimestamp":1740403022,"startTime":"0","endTime":"0","summary":"奥本海默：上调Biomarin Pharmaceutical(BMRN.US)评级，由Perform调整至优于大市评级, 目标价98.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/24211748352370.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BMRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111972741","title":"异动解读 | 财报远超预期,拜玛林制药盘前大涨10.52%","url":"https://stock-news.laohu8.com/highlight/detail?id=1111972741","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1111972741?lang=zh_cn&edition=full","pubTime":"2025-02-20 18:18","pubTimestamp":1740046705,"startTime":"0","endTime":"0","summary":"2025年第四季度财报出炉,拜玛林制药公司大幅超过了市场预期,这一利好消息推动公司股价在今日盘前大涨10.52%。\n\n拜玛林制药此前公布的2025年第四季度每股收益为0.92美元,远高于市场预期的0.53美元;季度销售额也创下7.4731亿美元的新高。此番罕见的业绩喜讯,令投资者看好公司进一步发展前景。\n\n作为领先的罕见疾病专业制药企业,拜玛林制药的出色表现得益于其管线和产品创新所带来的增长。投资界普遍认为,在需求不断增长的罕见疾病领域,公司将凭借领先优势开发新药并扩大收入来源,高速增长将延续。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["BMRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119520793","title":"异动解读 | 财报超预期利好发酵,拜玛林制药夜盘大涨9.72%","url":"https://stock-news.laohu8.com/highlight/detail?id=1119520793","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1119520793?lang=zh_cn&edition=full","pubTime":"2025-02-20 09:28","pubTimestamp":1740014916,"startTime":"0","endTime":"0","summary":"拜玛林制药公司在上周三夜盘交易中股价大涨9.72%,引发了投资者的广泛关注。股价暴涨的主要原因源自公司当季财报出现亮眼业绩,远超市场预期。拜玛林制药在2025年第四季度的每股收益和销售额均创下新高,分别达到0.92美元和7.4731亿美元,远高于分析师预期的0.53美元和7.1344亿美元。市场分析认为,在罕见疾病领域需求庞大的背景下,拜玛林制药凭借其领先优势,有望进一步开发新型疗法并扩大收入来源。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["BMRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1140129158","title":"异动解读 | 拜玛林制药盘后大涨7.83%,财报靓丽超预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1140129158","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1140129158?lang=zh_cn&edition=full","pubTime":"2025-02-20 05:33","pubTimestamp":1740000809,"startTime":"0","endTime":"0","summary":"拜玛林制药(BMRN)在周三的盘后交易中股价大涨7.83%,引发市场关注。\n\n盘后财报显示,拜玛林制药第四季度每股收益为0.92美元,远高于分析师预期的0.53美元。公司当季销售额也优于预期,达到7.4731亿美元,同比增长15.65%。由于业绩表现出色,公司股价在盘后呈现大涨态势。\n\n作为领先的罕见疾病治疗公司,拜玛林制药正努力扩大管线产品组合,并积极开拓新的疗法领域。这或许也为公司后续的业绩表现奠定基础。总体来看,本次财报利好消息的推动下,投资者对公司未来发展前景信心倍增,从而刺激股价出现明显上涨。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["BMRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142137647","title":"BioMarin制药第四季度调整后每股收益$0.92，超过预期的$0.53，销售额$7.4731亿，超出预期的$7.1344亿","url":"https://stock-news.laohu8.com/highlight/detail?id=1142137647","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1142137647?lang=zh_cn&edition=full","pubTime":"2025-02-20 05:08","pubTimestamp":1739999334,"startTime":"0","endTime":"0","summary":"公司报告季度销售额为$7.4731亿，超过分析师普遍预期的$7.1344亿，高出4.75%。以上内容来自Benzinga Earnings专栏，原文如下：Biomarin Pharmaceutical  reported quarterly earnings of $0.92 per share which beat the analyst consensus estimate of $0.53 by 73.58 percent. This is a 87.76 percent increase over earnings of $0.49 per share from the same period last year. The company reported quarterly sales of $747.31 million which beat the analyst consensus estimate of $713.44 million by 4.75 percent. This is a 15.65 percent increase over sales of $64","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"BioMarin制药第四季度调整后每股收益$0.92，超过预期的$0.53，销售额$7.4731亿，超出预期的$7.1344亿","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BMRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2504449484","title":"特朗普2.0时代即将开启，投资机会如何掘金？","url":"https://stock-news.laohu8.com/highlight/detail?id=2504449484","media":"招商基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2504449484?lang=zh_cn&edition=full","pubTime":"2025-01-20 10:36","pubTimestamp":1737340585,"startTime":"0","endTime":"0","summary":"美国候任总统唐纳德·特朗普将于美东时间1月20日12时正式宣誓就任美国第47任总统。特朗普2.0时代即将开启，有哪些投资机会可以布局？值得一提的是，科技股在特朗普任期内表现尤为突出，成为推动美股上涨的主要力量。在特朗普第一个任期内，美元整体表现相对弱势。4年任期内，美元指数累计下跌了10.53%。而纵观全球市场，在特朗普上一任期内，恒生科技指数涨幅超过147%，表现甚至略微优于纳斯达克指数。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250120103318abb12e8e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250120103318abb12e8e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["JBHT","ARGX","DDOG","PCTY","LULU","ALAB","REG","CHRD","TRMB","GTLB","BPOP","NTRS","MTCH","AMAT","CME","BK4086","NDAQ","BK4588","SNPS","ADI","LU2065731478.USD","ON","PLTR","INTC","Z","LIN","RYAAY","CASY","WWD","MKSI","AKAM","BSY","CBSH","WYNN","USAW.SI","ANSS","DOCU","CTSH","HBAN","TER","MANH","MRVL","BK4561","LECO","SWKS","CWST","NTRA","ASML","FSLR","MMYT",".IXIC","ONC","ENTG","NDSN","TCOM","ROST","REGN","SEIC","LPLA","PFG","EXPE","AUR","HOOD","ISRG","GOOGL","CCEP","PAA","INCY","FCNCA","BK4534","STLD","MNST","GMAB","META","HSIC","CZR","HLNE","SQQQ","LSTR","CHDN","WDC","SSNC","FER","AMGN","ILMN","PSQ","LU1815336091.USD","ALGN","LSCC","TXN","SFM","AGNC","AAPL","FSV","PAYX","FAST","QRVO","CSGP","MKTX","TROW","CFLT","EXAS","AAL","CSWI","ROKU","HST","SAIA","TSEM","TSYW.SI","EXE","ICLR","PCAR","DSGX","BRKR","EQIX","HON","MNDY","JKHY","AMZN","PEP","WTFC","CTAS","QID","CHRW","DASH","LI","MPWR","TECH","PARA","KDP","EBAY","SBAC","PODD","APA","CDW","NTNX","COO","EA","AMD","INSM","BK4550","MEDP","NFLX","NTAP","SOFI","NQmain","MIDD","ERIC","TMUS","USJW.SI","BK4585","QCOM","PNFP","NVMI","RKLB","ZM","AAON","ROIV","ROP","GEHC","CHKP","ESLT","OTEX","CHTR","ALNY","BKR","FTNT","AFRM","GLPI","ORLY","CINF","TSCO","DKNG","HTHT","LU0053671581.USD","NBIX","NWSA","DUOL","ODFL","GRAB","GILD","MNQmain","ULTA","ARM","MCHP","CSCO","BIIB","LNT","MRNA","SRPT","KHC","OLED","ITCI","AEP","FWONK","FTAI","ERIE","TLN","OKTA","BMRN","LAMR","CYBR","SIRI","TQQQ","RGLD","BK4593","NICE","DLTR","EVRG","MDB","TTWO","TW","CDNS","FRPT","LKQ","POOL","TSLA","AXON","CEG","HQY","RADX","COIN","BKNG","GNTX","QLD","PCVX","FOXA","INTU","ENPH","MTSI","MELI","NVIW.SI","SBUX","EWBC","COKE","NXPI","RPRX","COST","TPG","LOGI","IDXX","TTEK","PDD","CRWD","STX","ADBE","JD","SMCI","RVMD","RIVN","TTD","DPZ","AZN","DOX","MDLZ","ADSK","FOX","GEN","NTES","NVDA","LNW","FFIV","AVGO","BK4581","ZS","MSFT","CG","LU0757428866.USD","BPMC","WBA","CSX","MARA","FYBR","HOLX","RGEN","QXO","CPB","TEAM","CPRT","QQQ","PTC"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2503689242","title":"拜玛林制药盘中异动 临近收盘股价大跌5.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2503689242","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2503689242?lang=zh_cn&edition=full","pubTime":"2025-01-15 04:47","pubTimestamp":1736887645,"startTime":"0","endTime":"0","summary":"北京时间2025年01月15日04时47分，拜玛林制药股票出现异动，股价大幅跳水5.04%。截至发稿，该股报63.62美元/股，成交量115.596万股，换手率0.61%，振幅5.55%。拜玛林制药股票所在的生物技术行业中，整体跌幅为1.34%。拜玛林制药公司简介：拜玛林专注于是罕见病疗法。Genzyme公司通过与拜玛林公司的合资企业销售Aldurazyme，拜玛林公司则独立销售Naglazyme，Vimizim和Brineura。拜玛林还销售治疗罕见代谢性疾病PKU的Kuvan和Palynziq。拜玛林的 Roctavian于 2022 年在欧洲获批，2023 年在美国获批。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501150447269603ba7b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501150447269603ba7b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE0002270589.USD","BK4139","BMRN","IE00B19Z3581.USD","IE00B19Z3B42.SGD","IE00B7SZLL34.SGD","BK4566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2489411799","title":"拜玛林制药盘中异动 急速上涨5.05%报66.38美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2489411799","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489411799?lang=zh_cn&edition=full","pubTime":"2024-12-05 01:28","pubTimestamp":1733333325,"startTime":"0","endTime":"0","summary":"北京时间2024年12月05日01时28分，拜玛林制药股票出现异动，股价急速上涨5.05%。截至发稿，该股报66.38美元/股，成交量121.89万股，换手率0.64%，振幅5.53%。拜玛林制药股票所在的生物技术行业中，整体涨幅为0.46%。拜玛林制药公司简介：拜玛林专注于是罕见病疗法。拜玛林还销售治疗罕见代谢性疾病PKU的Kuvan和Palynziq。拜玛林的 Roctavian于 2022 年在欧洲获批，2023 年在美国获批。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024120501284598e56490&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024120501284598e56490&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","IE00B19Z3B42.SGD","BK4566","IE00B7SZLL34.SGD","IE0002270589.USD","BMRN","IE00B19Z3581.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.bmrn.com","stockEarnings":[{"period":"1week","weight":0.0547},{"period":"1month","weight":0.0631},{"period":"3month","weight":0.0551},{"period":"6month","weight":0},{"period":"1year","weight":0.0512},{"period":"ytd","weight":0.0155}],"compareEarnings":[{"period":"1week","weight":0.0013},{"period":"1month","weight":0.0138},{"period":"3month","weight":0.1061},{"period":"6month","weight":0.0844},{"period":"1year","weight":0.2047},{"period":"ytd","weight":0.0965}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Biomarin Pharmaceutical Inc.于1996年10月在特拉华州注册成立，并于1997年3月21日开始运营。该公司是一家全球性生物技术公司，致力于将基因发现的前景转化为对每位患者的生活产生深远影响的药物。T. BioMarin为代表重大未满足医疗需求的疾病和病症选择候选产品，这些疾病和病症具有很好的生物学理解，并提供了率先上市或提供优于现有产品的机会。该公司的产品组合由四个已获批准的产品和多个研究候选产品组成。","yearOnYearQuotes":[{"month":1,"riseRate":0.62963,"avgChangeRate":0.046047},{"month":2,"riseRate":0.481481,"avgChangeRate":0.016135},{"month":3,"riseRate":0.444444,"avgChangeRate":0.001463},{"month":4,"riseRate":0.481481,"avgChangeRate":-0.01987},{"month":5,"riseRate":0.518519,"avgChangeRate":0.008278},{"month":6,"riseRate":0.592593,"avgChangeRate":0.016302},{"month":7,"riseRate":0.666667,"avgChangeRate":0.040088},{"month":8,"riseRate":0.555556,"avgChangeRate":0.001992},{"month":9,"riseRate":0.444444,"avgChangeRate":-0.012768},{"month":10,"riseRate":0.407407,"avgChangeRate":-0.026394},{"month":11,"riseRate":0.814815,"avgChangeRate":0.061245},{"month":12,"riseRate":0.62963,"avgChangeRate":0.034544}],"exchange":"NASDAQ","name":"拜玛林制药","nameEN":"Biomarin Pharmaceutical"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"拜玛林制药(BMRN)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供拜玛林制药(BMRN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"拜玛林制药,BMRN,拜玛林制药股票,拜玛林制药股票老虎,拜玛林制药股票老虎国际,拜玛林制药行情,拜玛林制药股票行情,拜玛林制药股价,拜玛林制药股市,拜玛林制药股票价格,拜玛林制药股票交易,拜玛林制药股票购买,拜玛林制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"拜玛林制药(BMRN)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供拜玛林制药(BMRN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}